Login
$PLRX
$0.69 -$0.01 (1.41%) Live

$PLRX 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition
11 Aug 2026 8-K: Results of Operations and Financial Condition

FORTIFY, a Phase 1b indication expansion trial of PLN-101095,

13 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 9, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) increased the authorized size of the Board from seven to nine members, and, upon the recommendation of the Nominati...

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Pliant Therapeutics, Inc. (the “Company”) was held on June 11, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 61,914,664 shares of the Comp...

11 May 2026 8-K: Results of Operations and Financial Condition

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095

17 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 14, 2026, David E.I. Pyott, a Class I director on the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the...

30 Mar 2026 8-K: Other Events

As previously disclosed, on March 30, 2026, Pliant Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, or the 2026 Sales Agreement, with Leerink Partners LLC, as sales agent, with respect to an at-the-market offering progr...

11 Mar 2026 8-K: Results of Operations and Financial Condition

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial

03 Mar 2026 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders

This AMENDMENT TO STOCKHOLDER RIGHTS AGREEMENT (this “Amendment”) is made effective as of March 3, 2026. This Amendment is an amendment to that certain Stockholder Rights Agreement, dated as of March 12, 2025 (the “Rights Agreement”), by...

16 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 10, 2025, Pliant Therapeutics, Inc.’s (the “Company”) Board of Directors (the “Board”) appointed Minnie Kuo as Chief Operating Officer, effective immediately.

08 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 2, 2025, Pliant Therapeutics, Inc. (the “Company”) notified Éric Lefebvre, M.D., Chief Medical Officer, that Dr. Lefebvre’s employment with the Company will terminate effective December 15, 2025 (the “Separation Date”). The C...

06 Nov 2025 8-K: Results of Operations and Financial Condition

Oncology program advancing with data expected in the fourth quarter 2025BEACON-IPF close out activities to be completed in the fourth quarter 2025

24 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On October 20, 2025, Pliant Therapeutics, Inc. (the “Company”) received and accepted the resignation of Hans Hull as Chief Business Officer of the Company, effective that same day. Mr. Hull’s resignation was not due to a disagreement on ...

20 Oct 2025 8-K: Termination of a Material Definitive Agreement

On October 14, 2025, Pliant Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of $32.4 million, representing all outstanding principal, accrued and unpaid interest, fees, costs and expenses (the “Payoff Amount”) under t...

07 Aug 2025 8-K: Financial Statements and Exhibits

Previously announced workforce and operational realignment largely complete

09 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Pliant Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law” or “DGCL”), does hereby certify as follows:

08 May 2025 8-K: Results of Operations and Financial Condition

Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025

01 May 2025 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation

On May 1, 2025, Pliant Therapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 45% of its current employees. The Company expects to substantially complete the workforce reduction by the en...

13 Mar 2025 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more

South San Francisco, CA—March 13, 2025 – Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect sto...

03 Mar 2025 8-K: Results of Operations and Financial Condition

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support